Patents by Inventor Michael Z. Gilman

Michael Z. Gilman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • New applications of gene therapy technology
    Publication number: 20040265288
    Abstract: This invention provides new applications of regulated gene therapy relating to treatment of cancer and other disorders.
    Type: Application
    Filed: July 16, 2004
    Publication date: December 30, 2004
    Inventor: Michael Z. Gilman
  • Regulation of biological events using novel compounds
    Publication number: 20040082515
    Abstract: Materials and methods are disclosed for regulation of biological events such as target gene transcription and growth, proliferation or differentiation of engineered cells.
    Type: Application
    Filed: November 18, 2003
    Publication date: April 29, 2004
    Applicant: ARIAD Gene Therapeutics, Inc.
    Inventors: Timothy P. Clackson, Michael Z. Gilman, Dennis A. Holt, Terence P. Keenan, Leonard Rozamus, Wu Yang
  • Materials and method for treating or preventing pathogenic fungal infection
    Patent number: 6693189
    Abstract: This invention concerns derivatives of rapamycin and their antifungal uses. Also disclosed are materials and methods relevant to the identification of non-immunosuppressive anti-fungal rapamycin derivatives. Use of compounds, among others, of the formula is disclosed, where the various substitutents are as defined.
    Type: Grant
    Filed: July 10, 2001
    Date of Patent: February 17, 2004
    Assignee: Ariad Gene Therapeutics, Inc.
    Inventors: Dennis A. Holt, Terence P. Keenan, Timothy P. Clackson, Leonard Rozamus, Wu Yang, Michael Z. Gilman
  • Regulation of biological events using novel compounds
    Patent number: 6649595
    Abstract: Materials and methods are disclosed for regulation of biological events such as target gene transcription and growth, proliferation or differentiation of engineered cells.
    Type: Grant
    Filed: February 12, 2001
    Date of Patent: November 18, 2003
    Assignee: ARIAD Gene Therapeutics, Inc.
    Inventors: Timothy P. Clackson, Michael Z. Gilman, Dennis A. Holt, Terence P. Keenan, Leonard Rozamus, Wu Yang
  • Use of heterologous transcription factors in gene therapy
    Publication number: 20030143731
    Abstract: This invention provides novel materials and methods involving the heterologous expression of transcription factors which are useful for effecting transcription of target genes in genetically engineered cells or organisms containing them. Target gene constructs and other materials useful for practicing the invention are also disclosed.
    Type: Application
    Filed: October 23, 2001
    Publication date: July 31, 2003
    Applicant: ARIAD Gene Therapeutics, Inc.
    Inventors: Michael Z. Gilman, Sridaran Natesan
  • Compositions and method for regulation of transcription
    Patent number: 6479653
    Abstract: The present invention relates to novel fusion proteins which activate transcription, to nucleic acid constructs encoding the proteins and their use in the genetic engineering of cells.
    Type: Grant
    Filed: July 13, 2000
    Date of Patent: November 12, 2002
    Assignee: ARIAD Gene Therapeutics, Inc.
    Inventors: Sridaran Natesan, Michael Z. Gilman
  • Materials and method for treating or preventing pathogenic fungal infection
    Publication number: 20020165250
    Abstract: This invention concerns derivatives of rapamycin and their antifungal uses. Also disclosed are materials and methods relevant to the identification of non-immunosuppressive anti-fungal rapamycin derivatives.
    Type: Application
    Filed: July 10, 2001
    Publication date: November 7, 2002
    Inventors: Dennis A. Holt, Terence P. Keenan, Timothy P. Clackson, Leonard Rozamus, Wu Yang, Michael Z. Gilman
  • Regulation of biological events using novel compounds
    Publication number: 20020107189
    Abstract: Materials and methods are disclosed for regulation of biological events such as target gene transcription and growth, proliferation or differentiation of engineered cells.
    Type: Application
    Filed: February 12, 2001
    Publication date: August 8, 2002
    Inventors: Timothy P. Clackson, Michael Z. Gilman, Dennis A. Holt, Terence P. Keenan, Leonard Rozamus, Wu Yang
  • Heterologous transcription factors
    Patent number: 6306649
    Abstract: This invention provides novel materials and methods involving the heterologous expression of transcription factors which are useful for effecting transcription of target genes in genetically engineered cells or organisms containing them. Target gene constructs and other materials useful for practicing the invention are also disclosed.
    Type: Grant
    Filed: June 27, 1996
    Date of Patent: October 23, 2001
    Assignee: ARIAD Gene Therapeutics, Inc.
    Inventors: Michael Z. Gilman, Sridaran Natesan
  • Materials and method for treating or preventing pathogenic fungal infection
    Patent number: 6258823
    Abstract: This invention concerns derivatives of rapamycin and their antifungal uses. Also disclosed are materials and methods relevant to the identification of non-immunosuppressive antifungal rapamycin derivatives.
    Type: Grant
    Filed: November 2, 1998
    Date of Patent: July 10, 2001
    Assignee: Ariad Pharmaceuticals, Inc.
    Inventors: Dennis A. Holt, Terence P. Keenan, Timothy P. Clackson, Leonard Rozamus, Wu Yang, Michael Z. Gilman
  • Regulation of biological events using novel compounds
    Patent number: 6187757
    Abstract: Materials and methods are disclosed for regulation of biological events such as target gene transcription and growth, proliferation or differentiation of engineered cells.
    Type: Grant
    Filed: January 22, 1998
    Date of Patent: February 13, 2001
    Assignee: ARIAD Pharmaceuticals, Inc.
    Inventors: Timothy P. Clackson, Michael Z. Gilman, Dennis A. Holt, Terence P. Keenan, Leonard Rozamus, Wu Yang
  • Compositions and methods for regulation of transcription
    Patent number: 6117680
    Abstract: The present invention relates to novel fusion proteins which activate transcription, to nucleic acid constructs encoding the proteins and their use in the genetic engineering of cells.
    Type: Grant
    Filed: August 26, 1998
    Date of Patent: September 12, 2000
    Assignee: ARIAD Gene Therapeutics, Inc.
    Inventors: Sridaran Natesan, Michael Z. Gilman
  • Cell-free assay for compounds which activate or block inactivation of cell proliferation
    Patent number: 5607833
    Abstract: This invention pertains to a method of assessing the ability of a compound to block or activate cell proliferation by assessing its effect on a cellular signal transduction pathway whose activation results in cell proliferation. In the present method, a cell-free system is used to assess the ability of a compound to block or activate a signal transduction pathway which is activated by binding of a growth factor to a cell surface receptor with intrinsic tyrosine kinase activity and whose activation results in proliferation of the cells to which growth factor has bound. Cellular signal transduction involves multiple pathways, each consisting of one or more steps emanating from a specific protein bound to a single receptor which is specific for that protein and located on the cell surface or within the cell.
    Type: Grant
    Filed: April 11, 1995
    Date of Patent: March 4, 1997
    Assignee: Cold Spring Harbor Laboratory
    Inventors: Michael Z. Gilman, Henry B. Sadowski